Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 25, Numéro 4, Avril 2009
|
|
|---|---|---|
| Page(s) | 423 - 430 | |
| Section | Recherche et partenariat | |
| DOI | https://doi.org/10.1051/medsci/2009254423 | |
| Publié en ligne | 15 avril 2009 | |
- Schmid F, Smith DA. Is declining innovation in the pharmaceutical industry a myth ? Drug Discov Today 2005; 10 : 1031–9. [Google Scholar]
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3 : 711–4. [Google Scholar]
- Kola I, Hazuda D. Innovation and greater probability of success in drug discovery and development: from target to biomarkers. Curr Opin Biotechnol 2005; 16 : 644–6. [Google Scholar]
- Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today 2006; 11 : 355–63. [Google Scholar]
- Graeber TG, Sawyers CL. Cross-species comparisons of cancer signaling. Nat Genet 2005; 37 : 7–8. [Google Scholar]
- Kamb A. What’s wrong with our cancer models ? Nat Rev Drug Discov 2005; 4 : 161–5. [Google Scholar]
- Littman BH, Williams SA. The ultimate model organism: progress in experimental medicine. Nat Rev Drug Discov 2005; 4 : 631–8. [Google Scholar]
- Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5 : 741–54. [Google Scholar]
- Chen H, Churfat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84 : 491–5. [Google Scholar]
- Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405 : 857–65. [Google Scholar]
- Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003; 19(11) : 660–6. [Google Scholar]
- Pasanen MK. SLC01B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16 : 873–9. [Google Scholar]
- Wang Y, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009; 106 : 226–31. [Google Scholar]
- Caldwell MD. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111 : 4106–12. [Google Scholar]
- Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2 : 566–80. [Google Scholar]
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6 : 287–93. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.